CNS demyelinating disease following inactivated or viral vector SARS-CoV-2 vaccines: A case series
CONCLUSION: Our case series identifies the Sinopharm BBIBP-CorV and the AstraZeneca AZD1222 vaccines as potential triggers for CNS demyelinating diseases. Vaccine administration routines are not affected by these rare and coincidental events. However, these manifestations are not deniable and require serious attention. Further investigations are needed to clarify the actual mechanisms and real associations.PMID:36635139 | DOI:10.1016/j.vaccine.2023.01.003
Source: Vaccine - Category: Allergy & Immunology Authors: Narges Ebrahimi Mahsa Mazdak Vahid Shaygannejad Omid Mirmosayyeb Source Type: research
More News: Allergy & Immunology | AstraZeneca | Brain | Coronavirus | Corticosteroid Therapy | Covid Vaccine | COVID-19 | Multiple Sclerosis | Neurology | Respiratory Medicine | Rituxan | SARS | Tysabri | Vaccines | Women